{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:33Z","timestamp":1792001913200,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.lungcan.2016.12.005","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T13:15:58Z","timestamp":1481721358000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)"],"prefix":"10.1016","volume":"104","author":[{"given":"Marcello","family":"Tiseo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Damato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Migaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Gnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Camisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.12.005_bib0005","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0010","series-title":"World Health Organization Classification of Tumours","first-page":"145","article-title":"Pathology and genetics: tumors of the lung, pleura, thymus and heart","author":"Travis","year":"2004"},{"key":"10.1016\/j.lungcan.2016.12.005_bib0015","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ajcp\/111.6.826","article-title":"Thymoma, atypical thymoma, and thymic carcinoma: a novel conceptual approach to the classification of thymic epithelial neoplasms","volume":"111","author":"Suster","year":"1999","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0020","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0025","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.12.005_bib0035","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JTO.0000000000000115","article-title":"An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators","volume":"9","author":"Wynes","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0040","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1200\/JCO.2011.36.6427","article-title":"Impressive response with Imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma","volume":"29","author":"Buti","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0045","first-page":"6","article-title":"When a thymic carcinoma becomes a GIST","volume":"10","author":"Rossi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.12.005_bib0050","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43\u20139006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0055","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveal clinically relevant molecular distinctions between thymic and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jcp.48.5.447","article-title":"Oncogene proteins and proliferation antigens in thymomas: increase expression of epidermal growth factor receptor and Ki67 antigen","volume":"48","author":"Gilhus","year":"1995","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","article-title":"Epidermal growth factor receptor expression in invasive thymoma","volume":"128","author":"Henley","year":"2002","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0070","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/JTO.0b013e3181d86a30","volume":"5","author":"Aisner","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2006.07.003","article-title":"Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas","volume":"248","author":"Meister","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0085","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.12.005_bib0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2006.01.009","article-title":"Thymic carcinoma with epidermal growth factor receptor gene mutation","volume":"52","author":"Yamaguchi","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.12.005_bib0095","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multi-arm, multi-histology phase II basket trial","volume":"33","author":"Lopez-Chavez","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2559.2003.01663.x","article-title":"Expression of apoptosis-related markers and HER-2\/neu in thymic epithelial tumors","volume":"43","author":"Pan","year":"2003","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2016.12.005_bib0105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.lungcan.2012.05.108","article-title":"HER family receptor, and ligand status in thymic carcinoma","volume":"77","author":"Weissferdt","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.12.005_bib0110","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1093\/annonc\/mds147","article-title":"Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas","volume":"23","author":"Mimae","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2016.01.004","article-title":"Medical treatment involving investigational drug and genetic profile of thymic carcinoma","volume":"93","author":"Asao","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.12.005_bib0120","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/JTO.0b013e3181f1cab3","article-title":"Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas","volume":"5","author":"Sasaki","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0125","first-page":"4057","article-title":"Expression and mutational status of PDGFR in thymic tumours","volume":"29","author":"Meister","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0130","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/annonc\/mdr626","article-title":"Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors","volume":"23","author":"Schirosi","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Strobel","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"June","key":"10.1016\/j.lungcan.2016.12.005_bib0140","article-title":"Moving immune checkpoint blockade in thoracic tumors beyond NSCLC","author":"Facchinetti","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"9 Suppl. 2","key":"10.1016\/j.lungcan.2016.12.005_bib0145","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2016.12.005_bib0150","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J. Immunol. (Baltimore, MD 1950)"},{"issue":"3","key":"10.1016\/j.lungcan.2016.12.005_bib0155","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2016.12.005_bib0160","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinico-pathologic and prognostic implication of programmed death ligand 1 expression in thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0165","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-0434","article-title":"Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma","author":"Yokoyama","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0170","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/JTO.0b013e318292be18","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)","volume":"8","author":"Velcheti","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.005_bib0175","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216305554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216305554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T21:22:28Z","timestamp":1536182548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216305554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":35,"alternative-id":["S0169500216305554"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.12.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}